DOCSLIB.ORG

WHO Guidelines for the Treatment of Malaria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WHO Guidelines for the Treatment of Malaria GTMcover-production.pdf 11.1.2006 7:10:05 GUIDELINES FOR THE TREATMENT O F M A L A R I A GUIDELINES FOR THE TREATMENT OF MALARIA Guidelines for the treatment of malaria Guidelines for the treatment of malaria WHO Library Cataloguing-in-Publication Data Guidelines for the treatment of malaria/World Health Organization. Running title: WHO guidelines for the treatment of malaria. 1. Malaria – drug therapy. 2. Malaria – diagnosis. 3. Antimalarials – administration and dosage. 4. Drug therapy, Combination. 5. Guidelines. I. Title. II. Title: WHO guidelines for the treatment of malaria. ISBN 92 4 154694 8 (NLM classification: WC 770) ISBN 978 92 4 154694 2 WHO/HTM/MAL/2006.1108 © World Health Organization, 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20, avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication. For technical information, please contact: Dr P. Olumese Global Malaria Programme World Health Organization 20, avenue Appia – CH-1211 Geneva 27 Tel. +41 22 791 4424 Fax +41 22 791 4824 E-mail: [email protected] Printed in Switzerland Design: B. Duret – Cover: T. Cailler ii Contents Glossary v Abbreviations viii 1. Introduction 1 1.1 Background 1 1.2 Objectives and target audience 2 1.3 Methods used in developing the guidelines and recommendations 3 2. The clinical disease 5 3. Treatment objectives 7 3.1 Uncomplicated malaria 7 3.2 Severe malaria 7 4. Diagnosis of malaria 8 4.1 Clinical diagnosis 8 4.2 Parasitological diagnosis 9 4.3 Where malaria transmission is low–moderate and/or unstable 10 4.4 In stable high-transmission settings 10 4.5 Malaria parasite species identification 11 4.6 In epidemics and complex emergencies 11 5. Resistance to antimalarial medicines 12 5.1 Impact of resistance 12 5.2 Global distribution of resistance 12 5.3 Assessing resistance 13 6. Antimalarial treatment policy 14 6.1 Assessment of in vivo therapeutic efficacy 14 6.2 Criteria for antimalarial treatment policy change 15 7. Treatment of uncomplicated P. falciparum malaria 16 7.1 Assessment 16 7.2 Antimalarial combination therapy 16 7.3 The choice of artemisinin based combination therapy options 20 7.4 Practical aspects of treatment with recommended ACTs 23 7.5 Incorrect approaches to treatment 26 7.6 Additional aspects of clinical management 27 7.7 Operational issues in treatment management 29 7.8 Management of treatment failures 31 7.9 Treatment in specific populations and situations 32 7.10 Coexisting morbidities 38 iii Guidelines for the treatment of malaria 8. Treatment of severe falciparum malaria 41 8.1 Definition 41 8.2 Treatment objectives 41 8.3 Clinical assessment 42 8.4 Specific antimalarial treatment 42 8.5 Practical aspects of treatment 47 8.6 Follow-on treatment 48 8.7 Pre-referral treatment options 49 8.8 Adjunctive treatment 51 8.9 Continuing supportive care 53 8.10 Additional aspects of clinical management 54 8.11 Treatment during pregnancy 58 8.12 Management in epidemic situations 59 8.13 Hyperparasitaemia 60 9. Treatment of malaria caused by P. vivax, P. ovale or P. malariae 62 9.1 Diagnosis 62 9.2 Susceptibility of P. vivax, P. ovale and P. malariae to antimalarials 63 9.3 Treatment of uncomplicated vivax malaria 63 9.4 Treatment of severe vivax malaria 66 9.5 Treatment of malaria caused by P. ovale and P. malariae 66 9.6 Monitoring therapeutic efficacy for vivax malaria 66 10. Mixed malaria infections 68 11. Complex emergencies and epidemics 69 11.1 Diagnosis 69 11.2 Use of rapid diagnostic tests in epidemic situations 69 11.3 Management of uncomplicated malaria in epidemics 70 11.4 Areas prone to mixed falciparum/vivax malaria epidemics 70 11.5 Use of gametocytocidal drugs to reduce transmission 71 11.6 Anti-relapse therapy in vivax malaria epidemics 71 11.7 Mass treatment 71 Annexes Annex 1. The guidelines development process 77 Annex 2. Adaptation of WHO malaria treatment guidelines for use in countries 83 Annex 3. Pharmacology of antimalarial drugs 87 Annex 4. Antimalarials and malaria transmission 133 Annex 5. Malaria diagnosis 147 Annex 6. Resistance to antimalarials 155 Annex 7. Uncomplicated P. falciparum malaria 185 Annex 8. Malaria treatment and HIV/AIDS 198 Annex 9. Treatment of severe P. falciparum malaria 207 Annex 10. Treatment of P. vivax, P. ovale and P. malariae infections 225 Index 240 iv Glossary GLOSSARY Artemisinin-based combination therapy (ACT). A combination of artemisinin or one if its derivatives with an antimalarial or antimalarials of a different class. Asexual cycle. The life-cycle of the malaria parasite in host red blood cells (intra- erythrocytic development) from merozoite invasion to schizont rupture (merozoite → ring stage → trophozoite → schizont → merozoites). Duration approximately 48 h in Plasmodium falciparum, P. ovale and P. vivax;72h in P. malariae. Asexual parasitaemia. The presence in host red blood cells of asexual para- sites. The level of asexual parasitaemia can be expressed in several different ways: the percentage of infected red blood cells, the number of infected cells per unit volume of blood, the number of parasites seen in one microscopic field in a high-power examination of a thick blood film, or the number of parasites seen per 200–1000 white blood cells in a high-power examination of a thick blood film. Cerebral malaria. Severe falciparum malaria with coma (Glasgow coma scale <11, Blantyre coma scale <3). Malaria with coma persisting for >30 min after a seizure is considered to be cerebral malaria. Combination treatment (CT). A combination of two or more different classes of antimalarial medicines with unrelated mechanisms of action. Cure. Elimination of the symptoms and asexual blood stages of the malaria parasite that caused the patient or carer to seek treatment. Drug resistance. Reduced susceptibility of the causal agent to a drug. WHO defines resistance to antimalarials as the ability of a parasite strain to survive and/or multiply despite the administration and absorption of a medicine given in doses equal to – or higher than – those usually recommended but within the tolerance of the subject, with the caveat that the form of the drug active against the parasite must be able to gain access to the parasite or the infected red blood cell for the duration of the time necessary for its normal action. Resistance to antimalarials arises because of the selection of parasites with genetic mutations or gene amplifications that confer reduced susceptibility. Gametocytes. Sexual stages of malaria parasites present in the host red blood cells, which are infective to the anopheline mosquito. v Guidelines for the treatment of malaria Hypnozoites. Persistent liver stages of P. vivax and P. ovale malaria that remain dormant in host hepatocytes for a fixed interval (3–45 weeks) before maturing to hepatic schizonts. These then burst and release merozoites, which infect red blood cells. Hypnozoites are the source of relapses. Malaria pigment (haemozoin). A dark brown granular pigment formed by malaria parasites as a by-product of haemoglobin catabolism. The pigment is evident in mature trophozoites and schizonts. Merozoites. Parasites released into the host bloodstream when a hepatic or erythrocytic schizont bursts. These then invade the red blood cells. Monotherapy. Antimalarial treatment with a single medicine (either a single active compound or a synergistic combination of two compounds with related mechanism of action). Plasmodium. A genus of protozoan vertebrate blood parasites that includes the causal agents of malaria. Plasmodium falciparum, P. malariae, P. ovale and P. vivax cause malaria in humans. Pre-erythrocytic development. The life-cycle of the malaria parasite when it first enters the host. Following inoculation into a human by the female anopheline mosquito, sporozoites invade parenchyma cells in the host liver and multiply within the hepatocytes for 5–12 days, forming hepatic schizonts. These then burst liberating merozoites into the bloodstream, which subse- quently invade red blood cells. Radical cure. In P. vivax and P. ovale infections only, this comprises cure as defined above plus prevention of relapses. Rapid diagnostic test (RDT). An antigen-based stick, cassette or card test for malaria in which a coloured line indicates that plasmodial antigens have been detected. Recrudescence. The recurrence of asexual parasitaemia after treatment of the infection with the same infection that caused the original illness (in endemic areas now defined by molecular genotyping).
Load more

Recommended publications
  • Artemisinin Resistance: Current Status and Scenarios for Containment
    REVIEWS Artemisinin resistance: current status and scenarios for containment Arjen M. Dondorp*‡, Shunmay Yeung*§, Lisa White*‡, Chea Nguon§, Nicholas P.J. Day*‡, Duong Socheat§|| and Lorenz von Seidlein*¶ Abstract | Artemisinin combination therapies are the first-line treatments for uncomplicated Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant P. falciparum malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment. Parenteral In nearly all countries in which malaria is endemic, antimalarial properties (artemisinin) was identified, and Administered by injection. artemisinin combination therapies (ACT) are now the several more potent derivatives were synthesized, includ- recommended first-line therapy for uncomplicated ing artesunate, artemether and dihydroartemisinin11 Plasmodium falciparum malaria, a policy endorsed by (FIG. 1). Artemisinin derivatives have an excellent safety the WHO1. This change in policy followed a period profile in the treatment of malaria, a rapid onset of action of increasing failure rates with chloroquine and later and are active against the broadest range of stages in the sulphadoxine–pyrimethamine treatment, which arose life cycle of Plasmodium spp. compared with other anti- from the development of resistant P.
    [Show full text]
  • Meeting Report
    Meeting Report EXPERT CONSULTATION ON PLASMODIUM KNOWLESI MALARIA TO GUIDE MALARIA ELIMINATION STRATEGIES 1–2 March 2017 Kota Kinabalu, Malaysia Expert Consultation on Plasmodium Knowlesi Malaria to Guide Malaria Elimination Strategies 1–2 March 2017 Kota Kinabalu, Malaysia WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC RS/2017/GE/05/(MYS) English only MEETING REPORT EXPERT CONSULTATION ON PLASMODIUM KNOWLESI MALARIA TO GUIDE MALARIA ELIMINATION STRATEGIES Convened by: WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC Kota Kinabalu, Malaysia 1–2 March 2017 Not for sale Printed and distributed by: World Health Organization Regional Office for the Western Pacific Manila, Philippines September 2017 NOTE The views expressed in this report are those of the participants of the Expert Consultation on Plasmodium knowlesi Malaria to Guide Malaria Elimination Strategies and do not necessarily reflect the policies of the World Health Organization. This report has been prepared by the World Health Organization Regional Office for the Western Pacific for governments of Member States in the Region and for those who participated in the Expert Consultation on Plasmodium knowlesi Malaria to Guide Malaria Elimination Strategies, which was held in Kota Kinabalu, Malaysia from 1 to 2 March 2017. CONTENTS ABBREVIATIONS SUMMARY 1. INTRODUCTION ............................................................................................................................................. 1 2. PROCEEDINGS ...............................................................................................................................................
    [Show full text]
  • Cyclosporiasis: an Update
    Cyclosporiasis: An Update Cirle Alcantara Warren, MD Corresponding author Epidemiology Cirle Alcantara Warren, MD Cyclosporiasis has been reported in three epidemiologic Center for Global Health, Division of Infectious Diseases and settings: sporadic cases among local residents in an International Health, University of Virginia School of Medicine, MR4 Building, Room 3134, Lane Road, Charlottesville, VA 22908, USA. endemic area, travelers to or expatriates in an endemic E-mail: [email protected] area, and food- or water-borne outbreaks in a nonendemic Current Infectious Disease Reports 2009, 11:108–112 area. In tropical and subtropical countries (especially Current Medicine Group LLC ISSN 1523-3847 Haiti, Guatemala, Peru, and Nepal) where C. cayetanen- Copyright © 2009 by Current Medicine Group LLC sis infection is endemic, attack rates appear higher in the nonimmune population (ie, travelers, expatriates, and immunocompromised individuals). Cyclosporiasis was a Cyclosporiasis is a food- and water-borne infection leading cause of persistent diarrhea among travelers to that affects healthy and immunocompromised indi- Nepal in spring and summer and continues to be reported viduals. Awareness of the disease has increased, and among travelers in Latin America and Southeast Asia outbreaks continue to be reported among vulnera- [8–10]. Almost half (14/29) the investigated Dutch attend- ble hosts and now among local residents in endemic ees of a scientifi c meeting of microbiologists held in 2001 areas. Advances in molecular techniques have in Indonesia had C. cayetanensis in stool, confi rmed by improved identifi cation of infection, but detecting microscopy and/or polymerase chain reaction (PCR), and food and water contamination remains diffi cult.
    [Show full text]
  • Evolution of Plasmodium Falciparum Drug Resistance: Implications for the Development and Containment of Artemisinin Resistance
    Jpn. J. Infect. Dis., 65, 465-475, 2012 Invited Review Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance Toshihiro Mita1,2* and Kazuyuki Tanabe3,4 1Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, Tokyo 113-8421; 2Department of International Affairs and Tropical Medicine, Tokyo Women's Medical University, Tokyo 162-8666; and 3Laboratory of Malariology and 4Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan (Received March 15, 2012) CONTENTS: 1. Introduction 5. Artemisinin combination therapies (ACTs) and 2. Life cycle of P. falciparum resistance to artemisinins 3. Mechanisms of P. falciparum resistance to conven- 5–1. Artemisinin derivatives tional antimalarial drugs 5–2. ACTs 3–1. Chloroquine 5–3. Resistance and reduced susceptibility to arte- 3–2. Pyrimethamine and sulfadoxine misinins 4. Geographical spread of resistance to conventional 6. The Thailand-Cambodia border and the contain- antimalarial drugs ment of artemisinin resistance 4–1. Chloroquine 6–1. Thailand-Cambodia border: epicenter of drug 4–2. Pyrimethamine resistance 4–3. Sulfadoxine 6–2. Resistance and the Greater Mekong 6–3. Implications for the containment of artemisi- nin resistance 7. Concluding remarks SUMMARY: Malaria is a protozoan disease transmitted by the bite of the Anopheles mosquito. Among five species that can infect humans, Plasmodium falciparum is responsible for the most severe human malaria. Resistance of P. falciparum to chloroquine and pyrimethamine/sulfadoxine, conventionally used antimalarial drugs, is already widely distributed in many endemic areas. As a result, artemisinin- based combination therapies have been rapidly and widely adopted as first-line antimalarial treatments since the mid-2000s.
    [Show full text]
  • Identification of Cyclospora and Isospora from Diarrheic Patients in the Philippines
    Philippine Journal of Science RESEARCH NOTE 137 (1): 11-15, June 2008 ISSN 0031 - 7683 Identification of Cyclospora and Isospora from Diarrheic Patients in the Philippines Corazon C. Buerano1,2, Catherine B. Lago1, Ronald R. Matias1, Blanquita B. de Guzman1, Shinji Izumiyama3, Kenji Yagita3, and Filipinas F. Natividad1* 1Research and Biotechnology Division, St. Luke’s Medical Center 279 E. Rodriguez Sr. Ave., Quezon City 1102, Philippines 2Institute of Biology, University of the Philippines Diliman, Quezon City 1101, Philippines 3Department of Parasitology, National Institute of Infectious Diseases Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan In recent years, Cyclospora cayetanensis and Isospora belli have been recognized as causative organisms in cases of chronic diarrhea. The aim of this study was undertaken to determine the prevalence of enteric protozoa among diarrhea patients in the Philippines. Stools were collected and from 3456 samples examined, only one sample each was found positive for oocysts of Cyclospora cayetanensis and Isospora belli. Identification was based on autofluorescence of the oocysts with a 365 nm ultraviolet excitation filter. Both samples were obtained from male patients (18 and 73 years old, respectively) living in Iloilo province in the western islands of Visayas, Philippines. Both patients obtained their drinking water from deep wells. The identification of these two emerging pathogens, which are easily overlooked by less-trained technical staff, highlights the increasing awareness and technical capability on detecting these parasites in the Philippines. Key Words: Cyclospora, Isospora, enteric protozoa, diarrhea INTRODUCTION in tropical areas of south America and southeast Asia (Wittner et al. 1993), and has also been associated with Both Cyclospora and Isospora belongs to family diarrhea outbreaks in mental wards and day care centers Eimeridae, subphylum apicomplexa, which are (Marshall et al.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Manual for the Microscopical Diagnosis of Malaria in Man
    NATIONAL INSTITUTE OP HEALTH Bulletin No. 180 MANUAL FOR THE MICROSCOPICAL DIAGNOSIS OF MALARIA IN MAN Federal Security Agency U. S. PUBLIC HEALTH SERVICE Washington, D. C. FEDERAL SECURITY AGENCY U. S. PUBLIC HEALTH SERVICE National Institute of Health Bulletin No. 180 MANUAL FOR THE MICROSCOPICAL DIAGNOSIS OF MALARIA IN MAN By AIMEE WILCOX, Assistant Technologist U. S. Public Health Service From the Division of Infectious Diseases National Institute of Health UNITED STATES GOVERNMENT PRINTING OFFICE WASHINGTON : 1942 For sale by the Superintendent ofDocuments, Washington, D. C. - - - - - - Price 30 cents ORGANIZATION OF THE NATIONAL INSTITUTE OF HEALTH Thomas Parran, Surgeon General, United States Public Health Service Dyer, R. E, Director, National Institute of Health Division of Biologics Control.—Chief, Senior Surgeon M. Y. Yeldee. Division of Chemistry.—Chief, Professor C. S. Hudson. Division of Chemotherapy.—Chief, Surgeon W. H. Sebrell, Jr. Division of Industrial Hygiene.—Chief, Medical Director J. G. Townsend. Division of Infectious Diseases. —Chief, Senior Surgeon Charles Armstrong. Division of Pathology.—Chief, Senior Surgeon R. D. Lillie. Division of Public Health Methods. —Chief, G. St.J. Perrott. Division of Zoology.-—Chief, Professor W. H. Wright. National Cancer Institute. —Chief, Pharmacologist Director Carl Voegtlin. FOREWORD This manual begins with a description of the morphology and life history of the parasites of the different species of malaria, a descrip- tion which is clear and thorough and should be useful to both the beginner in the subject and to one who may wish a concise review. The author uses throughout the terminology recommended by the Sub-Committee of the Health Organization of the League of Nations.
    [Show full text]
  • Malaria Medicines Landscape
    2015 Malaria Medicines Landscape MARCH 2015 UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 [email protected] www.unitaid.org UNITAID is hosted and administered by the World Health Organization © 2015 World Health Organization (Acting as the host organization for the Secretariat of UNITAID) The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind either expressed or implied. The responsibility and use of the material lie with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This report was prepared by Katerina Galluzzo and Alexandra Cameron with support from UNITAID. All reasonable precautions have been taken by the author to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader.
    [Show full text]
  • Laboratory Diagnosis of Malaria Infection – a Short Review of Methods
    Laboratory diagnosis of malaria infection – A short review of methods Kesinee Chotivanich1 Kamolrat Silamut2 Nicholas P J Day2,3 1Department of Clinical Tropical Medicine, Faculty of Tropical Medicine. Mahidol University. Bangkok. Thailand 2Wellcome Trust-Mahidol University-Oxford Tropical Medicine Programme, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand 3Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Churchill Hospital, University of Oxford, Oxford, United Kingdom. Abstract diagnosis. Microscopic diagnosis of malaria is performed by staining Malaria is one of the most important tropical infectious diseases. The thick and thin blood films on a glass slide to visualize the malaria incidence of malaria worldwide is estimated to be 300–500 million parasite (2). Briefly, the patient’s finger is cleaned with alcohol, allowed clinical cases each year with a mortality of between one and three to dry and then the side of the fingertip is pricked with a sharp sterile million people worldwide annually. The accurate and timely diagnosis lancet or needle and two drops of blood are placed on a glass slide. To of malaria infection is essential if severe complications and mortality prepare a thick blood film, a blood spot is stirred in a circular motion are to be reduced by early specific antimalarial treatment. This review with the corner of the slide, taking care not make the preparation details the methods for the laboratory diagnosis of malaria infection. too thick, and allowed to dry without fixative. As they are unfixed the red cells lyse when a water based stain is applied. A thin blood film is Keywords: malaria, diagnosis, microscopy, rapid prepared by immediately placing the smooth edge of a spreader slide in the drop of blood, adjusting the angle between slide and spreader This article has previously been published in the Australian Journal of to 45°, and then smearing the blood with a swift and steady sweep Medical Science 2006; 27 (1): 11-15 and is reprinted here with kind along the surface.
    [Show full text]
  • Treatment of Malaria: Guidelines for Clinicians
    TREATMENT GUIDELINES Treatment of Malaria (Guidelines For Clinicians) If you wish to share your clinical experience, please contact us at: [email protected] Treatment Table The Treatment Table is available in PDF format at www.cdc.gov/malaria/pdf/treatmenttable.pdf Reporting We encourage clinicians to report all cases of laboratory-confirmed malaria to help CDC's surveillance efforts. Refer to our information on the Malaria Case Surveillance Report Form (http://www.cdc.gov/malaria/report.html). Evaluation and Diagnosis Because malaria cases are seen relatively rarely in North America, misdiagnosis by clinicians and laboratorians has been a commonly documented problem in published reports. However, malaria may be a common illness in areas where it is transmitted and therefore the diagnosis of malaria should routinely be considered for any febrile person who has traveled to an area with known malaria transmission in the past several months preceding symptom onset. Symptoms of malaria are generally non-specific and most commonly consist of fever, malaise, weakness, gastrointestinal complaints (nausea, vomiting, diarrhea), neurologic complaints (dizziness, confusion, disorientation, coma), headache, back pain, myalgia, chills, and/or cough. The diagnosis of malaria should also be considered in any person with fever of unknown origin regardless of travel history. Patients suspected of having malaria infection should be urgently evaluated. Treatment for malaria should not be initiated until the diagnosis has been confirmed by laboratory investigations. "Presumptive treatment" without the benefit of laboratory confirmation should be reserved for extreme circumstances (strong clinical suspicion, severe disease, impossibility of obtaining prompt laboratory confirmation, usually by microscopy). Laboratory diagnosis of malaria can be made through microscopic examination of thick and thin blood smears.
    [Show full text]
  • Slide 1 This Lecture Is the Second Part of the Protozoal Parasites. in This LECTURE We Will Talk About the Apicomplexans SPECIFICALLY the Coccidians
    Slide 1 This lecture is the second part of the protozoal parasites. In this LECTURE we will talk about the Apicomplexans SPECIFICALLY THE Coccidians. In the next lecture we will Lecture 8: Emerging Parasitic Protozoa part 1 (Apicomplexans-1: talk about the Plasmodia and Babesia Coccidia) Presented by Sharad Malavade, MD, MPH Original Slides by Matt Tucker, PhD HSC4933 1 Emerging Infectious Diseases Slide 2 These are the readings for this week. Readings-Protozoa pt. 2 (Coccidia) • Ch.8 (p. 183 [table 8.3]) • Ch. 11 (p. 301, 304-305) 2 Slide 3 Monsters Inside Me • Cryptosporidiosis (Cryptosporidum spp., Coccidian/Apicomplexan): Background: http://www.cdc.gov/parasites/crypto/ Video: http://animal.discovery.com/videos/monsters-inside-me- cryptosporidium-outbreak.html http://animal.discovery.com/videos/monsters-inside-me-the- cryptosporidium-parasite.html Toxoplasmosis (Toxoplasma gondii, Coccidian/Apicomplexan) Background: http://www.cdc.gov/parasites/toxoplasmosis/ Video: http://animal.discovery.com/videos/monsters-inside-me- toxoplasma-parasite.html 3 Slide 4 Learning objectives: Apicomplexan These are the learning objectives for this lecture. coccidia • Define basic attributes of Apicomplexans- unique characteristics? • Know basic life cycle and developmental stages of coccidian parasites • Required hosts – Transmission strategy – Infective and diagnostic stages – Unique character of reproduction • Know the common characteristics of each parasite – Be able to contrast and compare • Define diseases, high-risk groups • Determine diagnostic methods, treatment • Know important parasite survival strategies • Be familiar with outbreaks caused by coccidians and the conditions involved 4 Slide 5 This figure from the last lecture is just to show you the Taxonomic Review apicoplexans. This lecture we talk about the Coccidians.
    [Show full text]
  • New Trends in Anti-Malarial Agents
    Current Medicinal Chemistry, 2002, 9, 1435-1456 1435 New Trends in Anti-Malarial Agents 1,2 3 2 Michel Frédérich* , Jean-Michel Dogné* , Luc Angenot1 and Patrick De Mol 1 Laboratory of Pharmacognosy, Natural and Synthetic Drugs Research Center, University of Liège, CHU Sart- Tilman B36, 4000 Liège, Belgium 2 Laboratory of Medical Microbiology, University of Liège, CHU Sart-Tilman B23, 4000 Liège, Belgium 3 Laboratory of Medicinal Chemistry, Natural and Synthetic Drugs Research Center, University of Liège, CHU Sart-Tilman B36, 4000 Liège, Belgium Abstract: Malaria is the major parasitic infection in many tropical and subtropical regions, leading to more than one million deaths (principally young African children) out of 400 million cases each year (WHO world health report 2000). More than half of the world’s population live in areas where they remain at risk of malaria infection. During last years, the situation has worsened in many ways, mainly due to malarial parasites becoming increasingly resistant to several antimalarial drugs. Furthermore, the control of malaria is becoming more complicated by the parallel spread of resistance of the mosquito vector to currently available insecticides. Discovering new drugs in this field is therefore a health priority. Several new molecules are under investigation. This review describes the classical treatments of malaria and the latest discoveries in antimalarial agents, especially artemisinin and its recent derivatives as well as the novel peroxidic compounds. 1. INTRODUCTION virulence and drug resistance. P. falciparum may cause the conditions known as cerebral malaria, which is often fatal. Malaria is the major parasitic infection in many tropical and subtropical regions, leading to more than one million deaths The life cycle of the malaria parasite is complex [Fig.
    [Show full text]